Products Categories
| CAS No.: | 3689-50-7 |
|---|---|
| Name: | Oxomemazine |
| Molecular Structure: | |
|
|
|
| Formula: | C18H22N2O2S |
| Molecular Weight: | 330.451 |
| Synonyms: | 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine-5,5-dioxide;10H-Phenothiazine-10-propanamine, N,N,beta-trimethyl-, 5,5-dioxide;3-(5,5-Dioxido-10H-phenothiazin-10-yl)-N,N,2-trimethyl-1-propanamine;Alimemazine S,S-dioxide; |
| EINECS: | 222-996-8 |
| Density: | 1.202 g/cm3 |
| Melting Point: | 115° |
| Boiling Point: | 492.4 °C at 760 mmHg |
| Flash Point: | 251.6 °C |
| Appearance: | White crystals powder |
| PSA: | 49.00000 |
| LogP: | 4.31440 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 43224-75-52,2,6,6-Tetramethyl-4-(2-propyleneoxy) Piperidine
- 3689-50-7
oxomemazine
| Conditions | Yield |
|---|---|
| With dihydrogen peroxide |
- 41372-02-5Benzathine penicillin G
- 6846-50-0Propanoic acid,2-methyl-, 1,1'-[2,2-dimethyl-1-(1-methylethyl)-1,3-propanediyl] ester
- 183133-94-07,10-dimethoxy-10-DAB III
- 1070-64-0Octanoic acid,6,8-dichloro-, ethyl ester
- 1689-82-3Phenol,4-(2-phenyldiazenyl)-
- 1587-20-81,2,3-Propanetricarboxylicacid, 2-hydroxy-, 1,2,3-trimethyl ester
- 115661-82-07-Cyanoindoline
- 61788-93-0Amines, cocoalkyldimethyl
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Specification
Oxomemazine, with the CAS NO.3689-50-7, has the synonyms of 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine-5,5-dioxide; 10H-Phenothiazine-10-propanamine, N,N,beta-trimethyl-, 5,5-dioxide; 3-(5,5-Dioxido-10H-phenothiazin-10-yl)-N,N,2-trimethyl-1-propanamine; 6487 RP; 6847 R.P.; Alimemazine S,S-dioxide. Oxomemazine is an antihistamine and anticholinergic of the phenothiazine chemical class used for the treatment of cough.
Physical properties about Oxomemazine are: (1)ACD/LogP: 3.977; (2)ACD/LogD (pH 5.5): 0.96; (3)ACD/LogD (pH 7.4): 2.09; (4)ACD/BCF (pH 5.5): 1.00; (5)ACD/BCF (pH 7.4): 8.09; (6)ACD/KOC (pH 5.5): 3.30; (7)ACD/KOC (pH 7.4): 45.26; (8)#H bond acceptors: 4; (9)#Freely Rotating Bonds: 4; (10)Index of Refraction: 1.598 ; (11)Molar Refractivity: 93.748 cm3; (12)Molar Volume: 274.936 cm3; (13)Polarizability: 37.165 10-24cm3; (14)Surface Tension: 45.7599983215332 dyne/cm; (15)Density: 1.202 g/cm3; (16)Flash Point: 251.616 °C; (17)Enthalpy of Vaporization: 75.937 kJ/mol; (18)Boiling Point: 492.436 °C at 760 mmHg
You can still convert the following datas into molecular structure:
(1)InChI=1S/C18H22N2O2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)23(21,22)18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3;
(2)InChIKey=QTQPVLDZQVPLGV-UHFFFAOYSA-N;
(3)SmilesCC(CN1c2ccccc2S(=O)(=O)c3c1cccc3)CN(C)C
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | intraperitoneal | 185mg/kg (185mg/kg) | BEHAVIORAL: IRRITABILITY BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 57, Pg. 460, 1961. |
| mouse | LD50 | intravenous | 35mg/kg (35mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 135, Pg. 364, 1962. |
| mouse | LD50 | oral | 140mg/kg (140mg/kg) | Therapie. Vol. 26, Pg. 1203, 1971. | |
| mouse | LD50 | subcutaneous | 260mg/kg (260mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 135, Pg. 364, 1962. |